Provided By GlobeNewswire
Last update: May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025
Read more at globenewswire.comNASDAQ:BOLD (7/25/2025, 8:00:01 PM)
1.265
+0.01 (+1.2%)
Find more stocks in the Stock Screener